S. 3131 · 118th Congress

ORPHAN Cures Act

Introduced on Oct 25, 2023 by John Barrasso (R-WY). 3 cosponsors, 1 of them from another party. Latest action (Oct 25, 2023): Read twice and referred to the Committee on Finance.

Stage
Introduced
Introduced
Oct 25, 2023
Cosponsors
3
1 from the other party
Policy area
Health
Open in the Congress explorerCongress.govAlert me

Progress

The furthest stage the measure reached. Simple and concurrent resolutions do not go to the President.

  1. Introduced
  2. 2Reported by committee
  3. 3Passed one chamber
  4. 4Passed both chambers
  5. 5Sent to the President
  6. 6Became law

Official title

A bill to amend title XI of the Social Security Act to expand and clarify the exclusion for orphan drugs under the Drug Price Negotiation Program.

Summary

The Congressional Research Service has not summarized this measure yet.

Sponsor and cosponsors

Cosponsors by party as of the day they signed on. Original cosponsors signed on the day of introduction.

John BarrassoR-WYSponsor

Democrats · 1

Republicans · 2

Roll calls

Recorded votes on the measure. Most measures move by voice vote or unanimous consent, which record no individual positions.

No recorded roll call on this measure: it moved by voice vote or unanimous consent, or has not reached the floor.

History

Every action as published, oldest first. Roll calls link to how each member voted.

  1. Oct 25, 2023Introduced in Senate
  2. Oct 25, 2023 · SenateRead twice and referred to the Committee on Finance.

Committees

Committees and subcommittees the measure was referred to.

Agencies in its committees' jurisdiction

Analisa's mapping of committee jurisdiction to federal agencies; the bill may touch others, or none of these.

Who lobbied on it

Organizations whose lobbying reports (LD-2) name this measure. Spending is what they reported for those quarters on all issues, not on this measure alone.

  1. NOVARTIS CORPORATION14 reports
    $6.9M reported (all issues)Federal contractor: NOVARTIS PHARMACEUTICALS CORPORATION$36.2M in contracts, FY2026AI match · 100%
  2. SANOFI US SERVICES INC9 reports
    $12.8M reported (all issues)
  3. BIOTECHNOLOGY INNOVATION ORGANIZATION8 reports
    $6.7M reported (all issues)
  4. Patients Rising Now8 reports
    $80K reported (all issues)
  5. TAKEDA PHARMACEUTICALS AMERICA, INC.8 reports
    $2.9M reported (all issues)Federal contractor: TAKEDA PHARMACEUTICALS AMERICA, INC.$1.6M in contracts, FY2026AI match · 100%
  6. RARE DISEASE COMPANY COALITION7 reports
    $740K reported (all issues)
  7. ALEXION PHARMACEUTICALS INC.6 reports
    $390K reported (all issues)Federal contractor: ALEXION PHARMACEUTICALS INC$733.6K in contracts, FY2026AI match · 99%
  8. ALNYLAM PHARMACEUTICALS, INC.5 reports
    $220K reported (all issues)
  9. AstraZeneca Pharmaceuticals LP5 reports
    $3.8M reported (all issues)Federal contractor: ASTRAZENECA PHARMACEUTICALS LP$500 in contracts, FY2026AI match · 100%
  10. JOHNSON & JOHNSON SERVICES, INC.5 reports
    $8.9M reported (all issues)
  11. Travere Therapeutics5 reports
    $635K reported (all issues)Federal contractor: TRAVERE THERAPEUTICS, INC.$323.9K in contracts, FY2026AI match · 100%
  12. ACADIA PHARMACEUTICALS4 reports
    $1.4M reported (all issues)
  13. JAZZ PHARMACEUTICALS, INC.4 reports
    $2M reported (all issues)Federal contractor: JAZZ PHARMACEUTICALS, INC$369.3K in contracts, FY2026AI match · 100%
  14. LUNDBECK LLC4 reports
    $550K reported (all issues)Federal contractor: LUNDBECK LLCAI match · 99%
  15. UCB, INC.4 reports
    $1.1M reported (all issues)
  16. AARP3 reports
    $15.6M reported (all issues)
  17. GILEAD SCIENCES, INC.3 reports
    Federal contractor: GILEAD SCIENCES INCAI match · 100%
  18. PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA3 reports
  19. PFIZER INC.2 reports
    Federal contractor: PFIZER INCAI match · 100%
  20. Personalized Medicine Coalition2 reports
    $85K reported (all issues)
  21. Astria Therapeutics, Inc.1 report
    $40K reported (all issues)
  22. BIOMARIN PHARMACEUTICAL INC.1 report
    $470K reported (all issues)
  23. BRIDGEBIO PHARMA INC.1 report
    $140K reported (all issues)
  24. Healthcare Leadership Council1 report
    $110K reported (all issues)
  25. IONIS PHARMACEUTICALS, INC.1 report
  26. THE NEW ENGLAND COUNCIL1 report
    $10K reported (all issues)

Reports filed in 2023, 2024, 2025, 2026.

Sources and method

Every figure on this page traces to these records.

  • Bill status: bills and resolutions, sponsors, actions, subjects and CRS summaries (U.S. Government Publishing Office (GovInfo), from Congress.gov (Library of Congress))GovInfo Bill Status bulk data (Congress.gov; summaries by the Congressional Research Service) · data current to Oct 8, 2026 · loaded Oct 8, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Members of Congress, their terms, committees and identifiers (The @unitedstates project (from the Biographical Directory of the U.S. Congress, the House and the Senate))unitedstates/congress-legislators: legislators, committees and current committee membership · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: CC0 1.0 (public domain dedication)
  • House roll-call votes (Office of the Clerk, U.S. House of Representatives)Office of the Clerk, U.S. House of Representatives, roll-call vote records · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Senate roll-call votes and DW-NOMINATE scores (Voteview (UCLA Department of Political Science))Lewis, Jeffrey B., Keith Poole, Howard Rosenthal, Adam Boche, Aaron Rudkin, and Luke Sonnet (2026). Voteview: Congressional Roll-Call Votes Database. https://voteview.com/ · data current to Oct 3, 2026 · loaded Oct 3, 2026 · license: Free to use with the required citation
  • Lobbying disclosures (LD-1 registrations, LD-2 quarterly reports, LD-203 contribution reports) (Clerk of the U.S. House of Representatives)Clerk of the House, Lobbying Disclosure Act filings (organizations only; lobbyists' names are not loaded) · data current to Oct 7, 2026 · loaded Oct 7, 2026 · license: Public domain (U.S. Government work, 17 U.S.C. § 105)
  • Positions are shown only where a roll call recorded them; voice votes and unanimous consent record none.
  • Money and votes are shown side by side; neither explains the other.